Princeton Global Asset Management LLC Has $35,000 Holdings in Pfizer Inc. $PFE

Princeton Global Asset Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 62.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,431 shares of the biopharmaceutical company’s stock after selling 2,332 shares during the period. Princeton Global Asset Management LLC’s holdings in Pfizer were worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. lifted its position in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares in the last quarter. Amundi lifted its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new stake in Pfizer during the 1st quarter worth about $389,861,000. Goldman Sachs Group Inc. lifted its position in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Finally, Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.13.

Pfizer Stock Up 0.6%

Shares of PFE stock opened at $24.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm’s 50-day moving average is $24.89 and its 200-day moving average is $24.13. The stock has a market cap of $141.23 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.